RVNC

0.00

100.00% -3.65

Dopo l'orario di chiusura: 3.66 3.66 +

Revance Therapeutics Inc (RVNC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RVNC Giù? Forum Previsione

Precedente Chiudi:

$3.65

Aprire:

Volume 24 ore:

Relative Volume:

0.00

Capitalizzazione di mercato:

$381.02M

Reddito:

$234.04M

Utile/perdita netta:

$-323.92M

Rapporto P/E:

0.00

EPS:

-3.8

Flusso di cassa netto:

$-223.46M

1 W Prestazione:

-100.00%

1M Prestazione:

-100.00%

6M Prestazione:

-100.00%

1 anno Prestazione:

-100.00%

Intervallo 1D:

$0.00

Intervallo di 1 settimana:

$0.00

$3.66

Portata 52W:

$0.00

$7.56

Revance Therapeutics Inc Stock (RVNC) Company Profile

Nome

Revance Therapeutics Inc

Settore

Healthcare (1176)

Industria

Biotechnology (678)

Telefono

(615) 724-7755

Indirizzo

1222 DEMONBREUN STREET, NASHVILLE, CA

Dipendente

597

Cinguettio

@revance

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

RVNC's Discussions on Twitter

Confronta RVNC con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RVNC Revance Therapeutics Inc	0.00	381.02M	234.04M	-323.92M	-223.46M	-3.80
VRTX Vertex Pharmaceuticals Inc	455.22	117.23B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	665.46	72.75B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	636.02	38.65B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	268.99	34.69B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	114.50	27.45B	3.30B	-501.07M	1.03B	-2.1146

Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-29	Downgrade	Mizuho	Buy → Neutral
2024-01-09	Downgrade	Goldman	Buy → Neutral
2023-08-16	Aggiornamento	Exane BNP Paribas	Underperform → Neutral
2022-10-11	Iniziato	Morgan Stanley	Equal-Weight
2022-09-22	Iniziato	Goldman	Buy
2021-10-25	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-10-15	Reiterato	Needham	Buy
2020-08-11	Ripresa	Mizuho	Buy
2020-03-23	Downgrade	Goldman	Buy → Neutral
2019-12-02	Iniziato	Goldman	Buy
2019-10-30	Aggiornamento	Wells Fargo	Market Perform → Outperform
2019-06-11	Iniziato	Barclays	Overweight
2019-02-15	Iniziato	Wells Fargo	Market Perform
2019-02-14	Iniziato	H.C. Wainwright	Buy
2019-01-29	Iniziato	Stifel	Buy
2018-11-16	Aggiornamento	Guggenheim	Neutral → Buy
2018-09-17	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2018-04-20	Reiterato	Mizuho	Buy
2018-03-27	Iniziato	Needham	Buy
2018-03-05	Iniziato	Goldman	Buy
2018-01-09	Downgrade	Guggenheim	Buy → Neutral
2017-12-06	Iniziato	Guggenheim	Buy
2017-12-06	Reiterato	Mizuho	Buy
2017-11-27	Iniziato	Barclays	Overweight
2017-11-17	Iniziato	Mizuho	Buy
2017-08-22	Iniziato	JMP Securities	Mkt Outperform

Mostra tutto

Revance Therapeutics Inc Borsa (RVNC) Ultime notizie

Feb 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesRVNC - PR Newswire

Feb 11, 2025

Deadline Alert: Revance Therapeutics, Inc. (RVNC) Investors - GlobeNewswire

Feb 11, 2025

2025-02-11 | Shareholders that lost money on Revance Therapeutics, Inc. (RVNC) should contact Levi & Korsinsky about pending Class ActionRVNC | Press Release - Stockhouse Publishing

Feb 11, 2025

Feb 10, 2025

2025-02-10 | Shareholders that Lost Money on Revance Therapeutics, Inc. (RVNC) Should Contact Levi & Korsinsky about Pending Class ActionRVNC | Press Release - Stockhouse Publishing

Feb 10, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Feb 10, 2025

2025-02-10 | Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline | Press Release - Stockhouse Publishing

Feb 10, 2025

2025-02-10 | RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | Press Release - Stockhouse Publishing

Feb 10, 2025

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) Shareholders - PR Newswire

Feb 10, 2025

Feb 09, 2025

Class Action Filed Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

Feb 09, 2025

2025-02-09 | Class Action Filed Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 Deadline to JoinContact Levi & Korsinsky | Press Release - Stockhouse Publishing

Feb 09, 2025

Deltec Asset Management LLC Makes New $304,000 Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat

Feb 09, 2025

Feb 08, 2025

StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - ETF Daily News

Feb 08, 2025

Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by SG Americas Securities LLC - Defense World

Feb 08, 2025

Revance Therapeutics (NASDAQ:RVNC) Completes Merger with Crown Laboratories - Defense World

Feb 08, 2025

Crown Labs completes acquisition of Revance Therapeutics - MSN

Feb 08, 2025

Feb 07, 2025

Crown Laboratories Completes Acquisition of Revance Therapeutics - BioSpace

Feb 07, 2025

Major Aesthetics Industry Shakeup: Crown Labs Takes Over Revance in Strategic Power Move - StockTitan

Feb 07, 2025

Class Action Filed Against Revance Therapeutics, Inc. - GlobeNewswire

Feb 07, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance LawsuitRVNC - The Malaysian Reserve

Feb 07, 2025

StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat

Feb 07, 2025

Crown Labs completes acquisition of Revance Therapeutics By Investing.com - Investing.com Nigeria

Feb 07, 2025

Feb 06, 2025

GLAZER CAPITAL, LLC Acquires Significant Stake in Revance Therap - GuruFocus.com

Feb 06, 2025

RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.

Feb 06, 2025